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 ABSTRACT
Introduction: Arteriovenous fistula has been associated with improved morbimortality in hemodialysis patients. 
This has resulted in the “fistula First, catheter last” initiative. Nonetheless, the survival benefit of arteriovenous 
fistula has been questioned.
Methods: We conducted a retrospective observational study of all patients with non-end stage renal disease 
referred for first vascular access building between January 2014 and December 2015 in our hospital center. Our 
main goal was to evaluate the clinical impact and burden of building fistula in predialysis patients.
Results: During this period, of 178 first arteriovenous accesses placed, 87 patients remained in predialysis and 
91 patients started a chronic hemodialysis program. Median follow-up time by a nephrologist was 3.9 (2.5, 9.7) 
years. The mean age was 65.8±14.7 years, with 50.6% (n=90) of male patients. A higher rate of thrombosis in 
the predialysis group (26% vs 13%, p=0.037) was observed, but vascular access survival did not differ significantly 
(55% vs 67%, p=0.12). Mean vascular access placing was higher in the predialysis group (1.4±0.7 vs 1.2±0.4, 
p=0.006) and less interventions were requested (0.2±0.5 vs 0.3±0.6, p=0.10). Median time from vascular access 
placement to hemodialysis start was 22 (13, 41) months. At hemodialysis initiation, 10 (10.9%) patients used a 
central venous catheter; 80 (87.9%) patients an arteriovenous fistula, and one patient a graft. A total of 227 
vascular accesses were built; 121 (53.3%) in predialysis vs 106 (46.7%) in incident hemodialysis patients. In a 
multivariate model, the presence of a functional arteriovenous fistula at hemodialysis start was only associated 
with a trend to survival benefit (HR 0.38, 95% CI 0.14-1.00, p=0.05).
Conclusions: Our results stress the need for an individual approach and for future tools to assess the risk of 
death and progression to end-stage renal disease, therefore helping reduce the number of unutilized vascular 
accesses and rising cost of interventions.
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 INTRODUCTION
The general recommendation for vascular access (VA) 
placement in hemodialysis patients has been fistula first.1-4 
Historically, a survival benefit of arteriovenous fistula (AVF) 
over arteriovenous graft (AVG) and tunneled dialysis cath-
eter (TDC) has been suggested.5-8 This has been the main 
argument for guidelines such as the National Kidney 
Foundation Kidney Disease Outcomes Quality Initiative (K/
DOQI) and the Society for Vascular Surgery prioritizing AVF 
as the ideal long-term vascular access; AVG as the following 
preferred vascular access choice, and TDC the last 
option.9,10 Furthermore, these recommendations are sup-
ported by available data suggesting AVF has superior 
patency, fewer complications, less need of re-interventions, 
and ultimately improved patient survival.2,11
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Timely referral and placing of arteriovenous VA is 
one of the best preventive measures of catheter use at 
hemodialysis initiation, but defining the ideal timing of 
arteriovenous (AV) access placement, namely of AVF, 
remains challenging and not consensual10,12,13. Ques-
tions start to be raised when non-functionality rates of 
about 18% have been reported among the overall inci-
dent hemodialysis patients in Canada and the US popu-
lations, while a French study reported a rate of 9% 
nonfunctional AVF14-17. A nonfunctional AVF is associ-
ated with increased access-related complications and 
procedures18. Moreover, prior literature that describes 
the benefit of AVF over AVG and TDC is based on the 
access first used as opposed to the access first placed19. 
Furthermore, the competing risk of death must be con-
sidered, especially in the elderly, as it results in a con-
siderable number of patients with matured AVF who 
die before even starting hemodialysis18.
We aimed to retrospectively review the impact of 
vascular access placement in a cohort of predialysis 
patients in both vascular access-related complications 
and survival, and patient survival.
 METHODS
We retrospectively reviewed all patients in predialy-
sis who were referred to our specialized consulting at 
Centro Hospitalar Universitário do Porto, between Janu-
ary 2014 and December 2015, for preoperative physical 
examination, blood vessel assessment by doppler ultra-
sound (DU), and vascular access planning. Only first-
time referral for AV accesses were included in this 
review. Patients who had undergone prior VA surgery 
or who were re-starting hemodialysis (after kidney 
transplant, for instance) were excluded from the analy-
sis. The presence of a temporary or cuffed dialysis 
catheter was not an exclusion criterion. A total of 178 
patients were included (Figure I).
DU measurements were taken by a single nephrolo-
gist skilled in DU. The type of VA proposed by the con-
sulting nephrologist was dependent on patient past 
medical history, physical examination, and DU find-
ings20. The final choice of VA selected could be altered 
due to findings during the surgical proceedings. All 
patients were informed about the planned procedure 
and gave informed consent.
Hospital registries were reviewed for patient demo-
graphics, pertinent medical history, physical evaluation 
findings, preoperative imaging studies, and findings 
from the postoperative follow-up. All postoperative 
interventions were reviewed for indication, procedure 
type, and outcome. Patient was considered to carry a 
functional AVF when it could deliver adequate blood 
flow and was ready to cannulate at hemodialysis (HD) 
start.21 The end of VA follow-up was the beginning of 
HD for those enrolled in a chronic hemodialysis pro-
gram. VA follow-up in patients who remained predialy-
sis ended at the time of death or the first of November 
of 2016. All patients’ follow-up ended on the first of 
November of 2016.
Our primary endpoint was to assess the timing, com-
plications, and survival of first VA placed in patients 
with non-end-stage renal disease (ESRD) referred to 
VA creation. Secondary endpoints were progression to 
ESRD and patient survival.
Chi-square test was used to compare categorical 
variables. Kolmogorov-Smirnov’s test was performed 
to assess deviation from normal distribution. T test was 
used for normally distributed continuous variables. 
Mann-Whitney was applied to skewed variables. Log-
rank test was used to assess VA and patient cumulative 
survival, and respective curves were derived by Kaplan-
Meier method. Multivariate analysis of patient and VA 
survival was performed using Cox regression; only clini-
cally relevant or statistically significant variables were 
included in the model. All tests of significance were 
Figure 1
Flowchart of patient selection and vascular accesses placed
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two-sided and differences were considered significant 
when p≤0.05. Data are reported as percentages, mean 
± standard deviation (SD) or median and interquartile 
range (IQR) and 95% confidence interval (CI) as 
appropriate.
All statistical analyses were performed using Stata/
IC 14.0®.
 RESULTS
Between January 1st, 2014 and December 31th, 
2015, 178 adult patients with non-ESRD were evaluated 
for first VA creation. The mean age was 65.8±14.7 years, 
with 62.9% being older than 65 years-old, and 29.2% 
older than 75 years-old. Male patients represented 
50.6% (n=90). Patients with history of diabetes repre-
sented 45.5% (n=81), ischemic heart disease (IHD) 
25.3% (n=45), peripheral artery disease 19.1% (n=34), 
and cerebrovascular disease 31.5% (n=56). Median 
follow-up time by a nephrologist was 3.9 (IQR 2.5, 9.7) 
years and mean estimated glomerular filtration rate at 
referral was 16.8±5.2 ml/min/1.73m2. Baseline char-
acteristics of patients who progressed and did not pro-
gress to ESRD are presented in Table I.
It was possible to construct a VA in all patients; 177 
AVFs and one AVG. Median time from VA referral and 
VA placement was 22 days (IQR 13, 37). In 19 (10.7%) 
patients, VA placed differed from the one suggested 
by the Nephrologist. There were 86 (48.3%) radio-
cephalic AVF, 65 (36.5%) brachio-cephalic AVF, and 26 
(14.6%) brachio-basilic AVF. Median VA follow-up was 
24.4 (IQR 8.1, 46.9) months. One hundred and nine VA 
(61.2%) were patent at the end of follow-up; 52 (47.7%) 
radio-cephalic AVF, 42 (38.5%) brachio-cephalic AVF, 
14 (12.8%) brachio-basilic, and one AVG. By the end of 
the follow-up only 91 (51.1%) patients started hemo-
dialysis and 21 (11.8%) patients died before starting 
hemodialysis. Median time from VA placement and HD 
initiation was 22 (IQR 13, 41) months, 14 (7.9%) patients 
had the VA placed <6 months before HD start, 14 (7.9%) 
patients between 6-12 months before HD start, and 
150 (84.3%) more than one-year earlier. The first com-
plication experienced was primary failure in twenty-five 
(14.0%) patients, 20 (11.2%) AVF thrombosed, with 40 
(22.5%) AVF being abandoned. At the end of the study 
26% (n=23) vs 13% (n=12) of first AVF thrombosed in 
predialysis and HD group, respectively (p=0.037).
Eighty-four patients diagnosed with a potentially 
rectifiable VA complication underwent a total of 48 
interventions during the follow-up period (Table II); 29 
Table I
Patients’ baseline characteristics at the time of vascular access assessment.
Patients’ characteristics Predialysis Incident HD P-valueb
N 87 91
Age at referral, mean (SD) 66.8 (14.4) 64.9 (15.1) 0.39
Males 40 (46%) 50 (55%) 0.29
Diabetes 39 (45%) 42 (46%) 0.88
Hypertension 78 (90%) 86 (95%) 0.27
Peripheral Artery Disease 19 (22%) 15 (16%) 0.45
Ischemic Cardiac Disease 24 (28%) 21 (23%) 0.50
Cerebrovascular Disease 27 (31%) 29 (32%) 1.00
Chronic Kidney Disease etiology
Unknown
Diabetic nephropathy
ADPKD
Chronic GN
Ischemic nephropathy
Others
10 (11%)
23 (26%)
10 (11%)
15 (17%)
10 (11%)
19 (22%)
10 (11%)
29 (32%)
8 (9%)
18 (20%)
8 (9%)
18 (20%)
0.93
Follow-up time by a nephrologist (years), median (IQR) 4.8 (2.9,10.0) 3.6 (1.7, 8.6) 0.011
Estimated GFR, mean (SD) (ml/min/1,73m2)a 17.4 (5.1) 16.3 (5.3) 0.13
Patient follow-up time (months), median (IQR) 146.5 (88.1, 305.7) 137.7 (84.1, 317.3) 0.95
Patient survival (rate) 66 (76%) 64 (70%) 0.50
a Estimated Glomerular Filtration Rate (GFR) at referral using The Modification of Diet in Renal Disease equation.
b Data presented as mean ± SD, median (interquartile range), or frequency (percent), as appropriate. GN: glomerulonephritis; ADPKD: autosomal dominant polycystic kidney disease. 
A p-value<0.05 was considered statistically significant.
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(16.3%) patients experienced one intervention, 5 (2.8%) 
patients were submitted to 2 interventions, and 3 
(1.7%) patients underwent 3 procedures. Main vascular 
access characteristics are described in Table III. Of those 
starting hemodialysis, 10 (10.9%) patients started with 
TDC, 80 (87.9%) with AVF, and one with AVG. A total 
of 227 VA was built, of which 121 (53.3%) were in the 
predialysis group and 106 (46.7%) in incident HD 
patients, with 35 (19.6%) patients submitted to 2 VA 
placement, 4 (2.2%) patients submitted to 3 VA place-
ment and 2 patients submitted to 4 VA placement.
At the end of VA follow-up, 48 (55%) patients in pre-
dialysis and 61 (67%) patients in the group who started 
HD (p=0.12) had their first VA access patent. In a multi-
variate model including age, sex, diabetes, peripheral 
artery disease, cerebrovascular disease, ischemic heart 
disease (IHD), DU diameter of nurturing artery and out-
flow vein, and number of VA-related interventions, only 
IHD (HR 1.97, 95% CI 1.06-3.66, p=0.03) and cerebro-
vascular disease (HR 1.99, 95% CI 1.08-3.67, p=0.03) were 
significantly associated with worse VA survival.
Patient cumulative survival in the group who remained 
predialytic was 76% (n=66) and 70% (n=64) for those 
starting chronic HD (p=0.50). The presence of a func-
tioning AVF at HD start did not correlate with a statisti-
cally significant improved survival (HR 0.47, 95% CI 
0.17-1.24, p=0.129). But in a multivariate analysis includ-
ing gender, age, IHD, peripheral arterial disease, cerebro-
vascular disease, diabetes, and presence of functional 
AVF, age was associated with increased mortality (HR 
1.06, 95% CI 1.01-1.11, p=0.008), while functional AVF 
at HD start showed a trend towards improved survival 
(HR 0.38, 95% CI 0.14-1.00, p=0.05). When all patients 
were included in the model (HD and predialysis), only 
age was significantly associated with worse prognosis 
(HR 1.07, 95% CI 1.03-1.11, p<0.0001). Patient cumula-
tive survival curves can be observed in Figure 2.
Table III
First vascular access characteristics and complications.
Vascular access characteristics Predialysis Incident HD P-value
N 87 91
AV access placed
Radio-cephalic fistula
Brachio-cephalic fistula
Brachio-basilic fistula
AV Graft
44 (51%)
34 (39%)
9 (10%)
0 (0%)
42 (46%)
31 (34%)
17 (19%)
1 (1%)
0.28
Outflow vein diameter (mm)ª, median (IQR) 3.2 (2.8, 3.9) 3.3 (2.7, 4.4) 0.36
Nurturing artery diameter (mm) ª, median (IQR) 3 (2.6, 4.2) 3.4 (2.7, 4.5) 0.11
First complication
Primary failure
Juxta-anastomosis stenosis
Outflow vein stenosis
Central venous stenosis
Thrombosis
Steal syndrome
Others 
44 (52.3%)
12 (14%)
6 (7%)
6 (7%)
1 (1%)
12 (14%)
4 (5%)
3 (3%)
40 (47.6%)
13 (14%)
8 (9%)
8 (9%)
0 (0%)
7 (8%)
3 (3%)
1 (1%)
0.74
Number of proceduresb, median (IQR) / mean (SD) 0 (0,0) / 0.2 (0.5) 0 (0,1) / 0.3 (0.6) 0.03 / 0.10
Number of thrombosisb, median (IQR) / mean (SD) 0 (0, 1) / 0.3 (0.5) 0 (0, 0) / 0.1 (0.3) 0.02 / 0.02
Number of AV access placedb, median (IQR) / mean (SD) 1 (1, 2) / 1.4 (0.7) 1 (1, 1) / 1.2 (0.4) 0.02 / 0.006
AV access survival (rate) 48 (55%) 61 (67%) 0.12
Data presented as mean ± SD, median (interquartile range), or frequency (percent), as appropriate. A p-value<0.05 was considered statistically significant.
a Doppler ultrasound assessment at nephrologist consultation for VA planning.
b Even though these variables are skewed, for ease of reading, mean and SD are presented.
Table II
First intervention performed in the first-time AVF.
Type of procedurea N (%)
Balloon angioplasty 15 (8.4)
Thrombectomy 2 (1.1)
Surgery
Banding
Proximal anastomosis rebuilding
Arteriovenous ligationb
Open angioplasty
Graft interposition
15(8.4)
3
7
2
1
2
a Only the first procedure is considered in this table.
b Arteriovenous ligation resulting in VA closure was performed in one case because of 
AVF infection and in the second case because of draining vein with multiple stenosis, 
but anastomosis to basilic vein was feasible.
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 DISCUSSION
Optimizing vascular access outcomes continues to 
be an uppermost priority in the management of non-
ESRD and hemodialysis patients. The initial KDOQI 
guidelines published in 19971 and updated in 20012 
and 20069 as well as the “Fistula First Initiative” in 20033 
have consistently recommended preferential place-
ment of AVFs over AVGs or TDCs.
Several rationales for preferring AVFs over AVGs have 
been proposed: (1) AVFs have better longevity, (2) 
require fewer interventions to maintain long-term 
patency, (3) lower access-related costs, and (4) HD 
patients with an AVF have a lower mortality4,11,22.
The “Fistula First Initiative” has been questioned, 
particularly in the elderly. A recent study revealed 
that patients older than 80 years-old had similar sur-
vival outcomes whether an AVF or AVG was placed 
first; TDC had clearly the inferior outcome, and only 
50.7% of the patients who had an AVF as their first 
access placed actually used an AVF at the time of 
dialysis initiation15. Another recent observational 
study documented that older patients (≥67yo) who 
initiate HD with a central venous catheter (CVC), who 
had an AVF placed rather than an AVG, within 6 
months of dialysis initiation, were associated with 
better overall survival, despite longer CVC depend-
ence. Moreover, patients with AVF placement had 
lower rates of hospitalization due to all-cause infection 
and septicemia/bacteremia.23
In our study two thirds of the patients were older 
than 65 years-old, one third of them older than 75 
years-old, while showing an impressive rate of AVF use 
at HD initiation (87.9%). This happened at the expense 
of 227 arteriovenous (AV) accesses placed in 178 
patients, with only 91 patients engaging HD and 21 
(11.8%) deaths before even starting HD, in a 4-year 
period of follow-up.
Additionally, discrepancies remain in guidelines for 
optimal timing of vascular access placement: K/DOQI9 
guidelines suggest at least 6 months before HD start; 
the European Best Practice Guidelines12 recommend 
AVF creation at least 2-3 months before hemodialysis 
start, whereas the Society for Vascular Surgery10 defines 
a glomerular filtration rate of 20 to 25 ml/min/1.73m2 
as the criterion for fistula referral.
The timely creation of an AV access in patients with 
non-ESRD requires consideration of factors, such as 
patient preferences, life expectancy, likelihood of need-
ing and timing of hemodialysis start, AV access eligibil-
ity, and risk of complications. A Canadian population-
based study showed, when late-referral patients were 
excluded, that 39% of the remaining cohort had a pre-
dialysis AV access creation and 27% used an AV access 
at hemodialysis, with median time between AV access 
creation and hemodialysis start of 184 days.16 A French 
study based in the REIN registry documented an overall 
18% patients with nonfunctional AV access at hemo-
dialysis initiation; in those with a planned dialysis start, 
the interval between AV access creation and hemodi-
alysis initiation was <1 month for 14% of patients, 1–3 
months for 27%, 3–12 months for 38%, and >12 months 
for 21%.17
Our results revealed a median time from VA place-
ment and HD initiation of 22 months, 84.3% built a VA 
more than one-year before HD initiation, while 7.9% 
patients had the VA placed between 6-12 months, and 
7.9% <6 months before HD start, respectively. This find-
ing is possibly related to challenges in the anticipation 
of HD onset because of nonlinear chronic kidney dis-
ease progression, reversible acute kidney injury and 
the ultimate concern for a functional AVF at the time 
of HD initiation. A strategy of closer follow-up of 
patients eligible for an AVF may facilitate determination 
of the ideal timing for AV access creation. Optimal tim-
ing should also involve the avoidance of AV access crea-
tion in patients who will not begin dialysis.
Figure 2
Kaplan‑Meier survival curves of predialysis and incident hemodialysis 
patients, respectively
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A decision analysis assessing the ideal timing for 
AV access referral through Monte Carlo simulation 
found that earlier referral for older patients had vir-
tually no impact on rates of successful AV access use 
at hemodialysis initiation, but increased the frequen-
cy of unnecessary AV access creation.24 This outcome 
was due mainly to mortality before hemodialysis 
initiation, which suggests that early VA placement in 
patients with a high comorbidity burden may often 
be pointless. Furthermore, a population-based study 
conducted in Canada showed that patients with a 
higher Deyo-Charlson Comorbidity Index were more 
likely to start hemodialysis after AVF creation, when 
age, sex, and the competing risk of death were 
considered.25
We registered 38.8% (n=69) non-functional AVF at 
the end of the study. In the multivariate analysis only 
IHD and cerebrovascular disease were associated with 
worse VA survival. The reason for the rate of failure 
seen in our cohort might be explained by an exhaustive 
attempt to create autologous fistulas. It has been pro-
posed that, in the elderly, an AVG may be a preferable 
choice of second VA in a specific group of patients, 
such as females, blacks, and those with peripheral vas-
cular disease.26 In addition to a clinical-tree decision, 
DU assessment may help select the best VA option for 
each individual patient.
Our study has some limitations. First, due to its 
observational nature we are only able to infer asso-
ciations rather than causality. Second, our study is 
probably underpowered to detect a survival benefit, 
yet we did find a marginal survival improvement from 
functional AVF at HD initiation, with age being the 
most important mortality predictor in our model. 
Brown et al. and Quinn et al. described that among 
patients initiating HD with a CVC, those who under-
went AVF placement before HD initiation had superior 
survival to those without predialysis access surgery, 
despite having a very similar profile of comorbidi-
ties.27,28 This was even if the AVF failed to mature 
and was never used for HD, and thus with no correla-
tion with a shorter CVC dependence period. This 
finding suggests that the decision to place an AVF in 
a patient itself reflects a healthier patient in ways 
that are not captured by compiling a list of known 
comorbidities. Moreover, an observational study sug-
gested that the association between access type and 
mortality was nearly identical in models excluding 
and including access complications (HR 2.00; 95% CI 
1.55-2.58 vs HR 2.01 95% CI 1.56-2.59 for CVC versus 
AVF, respectively).29
Regarding costs, a recent study suggests that even 
though AVF have been considered the most cost-effec-
tive option, this benefit decreases with rising age and 
lower life expectancy.30
In conclusion, a high AVF placement rate was pos-
sible in the K/DOQI era. Nevertheless, the improving 
number of functional AVF can be at the expense of an 
exceeding number of futile VA created, increased rate 
of failing AVFs and rising burden of interventions. To 
date no randomized controlled trial has been designed 
to access the real benefit from predialysis AVF place-
ment. Our results highlight the aging of our population 
and the need for an individual approach and for future 
tools which can help predict the risk of death and pro-
gression to ESRD.
Disclosure of potential conflicts of interest: none declared
References
 1. National Kidney Foundation-Dialysis Outcomes Quality Initiative. NKF-DOQI clinical 
practice guidelines for vascular access. Am J Kidney Dis 1997;30(3):S150–S191.
 2. NKF-K/DOQI: III. NKF-K/DOQI clinical practice guidelines for vascular access: update 
2000. Am J Kidney Dis 2001;37(1):S137–S181.
 3. Lok CE. Fistula first initiative: advantages and pitfalls. Clin J Am Soc Nephrol 2007;2:1043–
1053.
 4. Allon M. Current management of vascular access. Clin J Am Soc Nephrol 2007;2:786–800.
 5. Dhingra RK, Young EW, Hulbert-Shearon TE, Leavey SF, Port FK. Type of vascular access 
and mortality in U.S. hemodialysis patients. Kidney Int 2001;60:1443–1451.
 6. Woods JD, Port FK. The impact of vascular access for haemodialysis on patient morbid-
ity and mortality. Nephrol Dial Transplant 1997;12:657–659.
 7. Polkinghorne KR, McDonald SP, Atkins RC, Kerr PG. Vascular access and all-cause mortal-
ity: a propensity score analysis. J Am Soc Nephrol 2004;15:477–486.
 8. Xue JL, Dahl D, Ebben JP, Collins AJ. The association of initial hemodialysis access type 
with mortality outcomes in elderly Medicare ESRD patients. Am J Kidney Dis 
2003;42:1013–1019.
 9. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice 
Recommendations for 2006 updates: hemodialysis adequacy, peritoneal dialysis ade-
quacy and vascular access. Am J Kidney Dis 2006;48(1):S1–S322.
 10. Sidawy AN, Spergel LM, Besarab A, Allon M, Jennings WC, Padberg FT Jr, et al. The 
Society for Vascular Surgery: clinical practice guidelines for the surgical placement and 
maintenance of arteriovenous hemodialysis access. J Vasc Surg 2008;48(5 Suppl):2S–25S.
 11. Allon M, Robbin ML. Increasing arteriovenous fistulas in hemodialysis patients: Problems 
and solutions. Kidney Int 2002;62:1109– 1124.
 12. Tordoir J, Canaud B, Haage P, Konner K, Basci A, Fouque D, et al. EBPG on Vascular Access. 
Nephrol Dial Transplant 2007;22(2):ii88–117.
 13. 2006 Updates Clinical Practice Guidelines and Recommendations [Internet]. Available 
at:https://www.kidney.org/sites/default/files/docs/12-50-0210_jag_dcp_guidelines-
va_oct06_sectionc_ofc.pdf. [cited Jan 5 2016].
 14. Grubbs V, Wasse H, Vittinghoff E, Grimes BA, Johansen KL. Health status as a potential 
mediator of the association between hemodialysis vascular access and mortality. Nephrol 
Dial Transplant 2014;29(4):892–898.
 15. Malas MB, Canner JK, Hicks CW, Arhuidese IJ, Zarkowsky DS, Qazi U, et al. Trends in 
incident hemodialysis access and mortality. JAMA Surg 2015;150(5):441–448.
 16. Al-Jaishi AA, Lok CE, Garg AX, Zhang JC, Moist LM. Vascular access creation before 
hemodialysis initiation and use: a population-based cohort study. Clin J Am Soc Nephrol 
2015;10(3):418–427.
 17. Alencar de Pinho N, Coscas R, Metzger M, Labeeuw M, Ayav C, Jacquelinet C, Massy ZA, 
Stengel B; French REIN registry. Vascular access conversion and patient outcome after 
hemodialysis initiation with nonfunctional arteriovenous access: a prospective registry-
based study. BMC Nephrol. 2017 Feb 22;18(1):74..
 18. DeSilva RN, Patibandla BK, Vin Y, Narra A, Chawla V, Brown RS, et al. Fistula first is not 
always the best strategy for the elderly. J Am Soc Nephrol 2013;24(8):1297–1304.
 19. Yuo TH, Chaer RA, Dillavou ED, Leers SA, Makaroun MS. Patients started on hemodialy-
sis with tunneled dialysis catheter have similar survival after arteriovenous fistula and 
arteriovenous graft creation. J Vasc Surg 2015;62(6):1590-–1597.e2.
Are we building too many arteriovenous fistulas? A single-center experience
280    Port J Nephrol Hypert 2017; 31(4): 274-280
 20. Barreto P, Almeida P, de Matos N, Queirós JA, Pinheiro J, Silva F, et al. Preoperative 
vessel mapping in chronic kidney disease patients – a center experience. J Vasc Access 
2016;17(4):320–327.
 21. Sidawy AN, Gray R, Besarab A, Henry M, Ascher E, Silva M, Jr, et al. Recommended 
standards for reports dealing with arteriovenous hemodialysis accesses. J Vasc Surg 
2002;35:603–610.
 22. Lok CE, Foley R. Vascular access morbidity and mortality: trends of the last decade. Clin 
J Am Soc Nephrol 2013;8:1213–1219.
 23. Lee T, Thamer M, Zhang Q, Zhang Y, Allon M. Vascular access type and clinical outcomes 
among elderly patients on hemodialysis. Clin J Am Soc Nephrol 2017;10.pii: 
CJN.01410217.
 24. Shechter SM, Skandari MR, Zalunardo N. Timing of arteriovenous fistula creation in 
patients with CKD: a decision analysis. Am J Kidney Dis 2014 Jan;63(1):95-103.
 25. Oliver MJ, Quinn RR, Garg AX, Kim SJ, Wald R, Paterson JM. Likelihood of starting dialy-
sis after incident fistula creation. Clin J Am Soc Nephrol 2012;7(3):466–471.
 26. Hod T, Goldfarb-Rumyantzev AS, Patibandla BK, Narra A, Brown RS. Second vascular 
access after failure of the first fistula in the elderly. Clin Nephrol 2016;86:253–261.
 27. Brown RS, Patibandla BK, Goldfarb-Rumyantzev AS. The survival benefit of “Fistula First, 
Catheter Last” in hemodialysis is primarily due to patient factors. J Am Soc Nephrol 
2016;28:645–652.
 28. Quinn RR, Oliver MJ, Devoe D, Poinen K, Kabani R, Kamar F, et al. The effect of predi-
alysis fistula attempt on risk of all-cause and access- related death. J Am Soc Nephrol 
2017,28:613–620.
 29. Ravani P, Quinn R, Oliver M, Robinson B, Pisoni R, Pannu N, et al. Examining the asso-
ciation between hemodialysis access type and mortality: the role of access complications. 
Clin J Am Soc Nephrol 2017;12:955–964.
 30. Hall RK, Myers ER, Rosas SE, O’Hare AM, Colón-Emeric CS. Choice of hemodialysis access 
in older adults: a cost-effectiveness analysis. Clin J Am Soc Nephrol 2017;12:947–954.
Correspondence to:
Carla Leal Moreira, MD
Nephrology department, Centro Hospitalar Universitário do Porto, 
Hospital Geral de Santo António
Largo Prof. Abel Salazar, 4099-001 Porto
E-mail: moreira.l.s.carla@gmail.com
Carla Leal Moreira, Vanda Teixeira, Lígia Bessa, José Queirós, Fernanda Silva, António Cabrita
